ID: ALA2419502

Max Phase: Preclinical

Molecular Formula: C20H19N3O3S

Molecular Weight: 381.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)NCc1cccnc1

Standard InChI:  InChI=1S/C20H19N3O3S/c24-20(23-15-17-5-4-12-21-13-17)22-14-16-8-10-19(11-9-16)27(25,26)18-6-2-1-3-7-18/h1-13H,14-15H2,(H2,22,23,24)

Standard InChI Key:  CLJIQUIFVDETGQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 381.46

Molecular Weight (Monoisotopic): 381.1147

AlogP: 2.91

#Rotatable Bonds: 6

Polar Surface Area: 88.16

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.73

CX Basic pKa: 4.82

CX LogP: 2.27

CX LogD: 2.27

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.69

Np Likeness Score: -1.46

References

1. Dragovich PS, Bair KW, Baumeister T, Ho YC, Liederer BM, Liu X, Liu Y, O'Brien T, Oeh J, Sampath D, Skelton N, Wang L, Wang W, Wu H, Xiao Y, Yuen PW, Zak M, Zhang L, Zheng X..  (2013)  Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,  23  (17): [PMID:23899614] [10.1016/j.bmcl.2013.06.090]

Source

Source(1):

• Scientific Literature